Decision Diagnostics Corp (DECN) 0.2151 $DECN
DECN Plans New Legal Challenge After LifeScan (J&J) Admits to Using Sworn Testimony From Expert With Falsified Credentials
Marketwired - Wed Jan 14, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that on December 19, 2014, the company and its subsidiary Pharma Tech Solutions were notified through a letter addressed to the District Court Northern District of California and authored by the lead counsel for Lifescan Inc. (Johnson & Johnson) and LifeScan Scotland, Ltd. (Lifescan) that the primary expert witness they had engaged to provide two separate expert opinions and declarations on LifeScan's behalf has been revealed to have falsified his credentials.
JNJ: 99.62 (+1.18)
DECN Initiates End Game Strategy For Litigation With Division of Johnson & Johnson
ACCESSWIRE - Wed Dec 03, 8:20AM CST
Company receives favorable opinion in patent infringement case with J&J, declines offer of mediation but will agree to direct back-channel settlement talks
JNJ: 99.62 (+1.18)
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
ACCESSWIRE - Wed Nov 05, 8:26AM CST
900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
JNJ: 99.62 (+1.18)
David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling
Marketwire - Mon Aug 11, 8:20AM CDT
Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer of an exclusive worldwide sales, service and regulatory processes agent for its popular GenStrip(TM) glucose test strip, specifically designed to work with Johnson & Johnson's LifeScan Ultra family of glucose testing meters, announced today that on August 6, 2014, the United States Patent and Trademark Office, Patent Trial and Appeal Board has sustained, in a final ruling, the company's challenge to Johnson & Johnson Lifescan's Patent 7,250,105, specifically "claims 1-3 ... for obviousness, ... by a preponderance of the evidence." These three claims are used by J&J Lifescan as the foundation of their patent infringement lawsuit against DECN and Pharma Tech. The USPTO Judge Panel has ruled these claims as "unpatentable."
JNJ: 99.62 (+1.18)
DECN Plans New Legal Challenge After LifeScan (J&J) Admits to Using Sworn Testimony From Expert With Falsified Credentials
Marketwired - Wed Jan 14, 8:20AM CST
Decision Diagnostics Corp. (OTC PINK: DECN), the manufacturer, quality plan administrator and the exclusive worldwide sales, service and regulatory processes agent for the popular GenStrip(TM) 50, the FDA cleared Green Glucose Test Strip, specifically designed to work with the market leading Johnson & Johnson's LifeScan Ultra family of glucose testing meters, today announced that on December 19, 2014, the company and its subsidiary Pharma Tech Solutions were notified through a letter addressed to the District Court Northern District of California and authored by the lead counsel for Lifescan Inc. (Johnson & Johnson) and LifeScan Scotland, Ltd. (Lifescan) that the primary expert witness they had engaged to provide two separate expert opinions and declarations on LifeScan's behalf has been revealed to have falsified his credentials.
JNJ: 99.62 (+1.18)
DECN Initiates End Game Strategy For Litigation With Division of Johnson & Johnson
ACCESSWIRE - Wed Dec 03, 8:20AM CST
Company receives favorable opinion in patent infringement case with J&J, declines offer of mediation but will agree to direct back-channel settlement talks
JNJ: 99.62 (+1.18)
DECN's Subsidiary Initiates First in Industry Social Media Marketing Campaign for Genstrip50
ACCESSWIRE - Wed Nov 05, 8:26AM CST
900,000 Current Users of J&J Lifescan Ultra Products Targeted With Expected Generation of $75 Million Annually at 20% EBITA
JNJ: 99.62 (+1.18)
David Defeats Goliath (Again), DECN and Pharma Tech Solutions Awarded Victory Over Johnson & Johnson Lifescan in USPTO Final Ruling
Marketwire - Mon Aug 11, 8:20AM CDT
Decision Diagnostics Corp. (PINKSHEETS: DECN), the manufacturer of an exclusive worldwide sales, service and regulatory processes agent for its popular GenStrip(TM) glucose test strip, specifically designed to work with Johnson & Johnson's LifeScan Ultra family of glucose testing meters, announced today that on August 6, 2014, the United States Patent and Trademark Office, Patent Trial and Appeal Board has sustained, in a final ruling, the company's challenge to Johnson & Johnson Lifescan's Patent 7,250,105, specifically "claims 1-3 ... for obviousness, ... by a preponderance of the evidence." These three claims are used by J&J Lifescan as the foundation of their patent infringement lawsuit against DECN and Pharma Tech. The USPTO Judge Panel has ruled these claims as "unpatentable."
JNJ: 99.62 (+1.18)
